Inhibition of the inhaled allergen challenge response by the CRTH2 antagonist OC000459 in patients with asthma Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease Year: 2010
The effect of a leukotriene antagonist, pranlukast, on allergen-induced airway responses and circulating dendritic cells in subjects with atopic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 414s Year: 2003
Inhaled IL-4/IL-13 antagonist decreases response to antigen challenge in atopic asthmatic subjects Source: Eur Respir J 2007; 30: Suppl. 51, 490s Year: 2007
CCR4 ligands are up-regulated in the airways of atopic asthmatics after segmental allergen challenge Source: Eur Respir J 2004; 23: 876-884 Year: 2004
The inhaled PDE4 inhibitor UK-500,001 does not significantly inhibit airway responses to allergen and histamine Source: Annual Congress 2007 - New drugs for asthma Year: 2007
The CysLT1 receptor antagonist montelukast inhibits mast cell activation induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016
Chemokine and cytokine production in the airway from atopic asthmatics after segmental allergen challenge Source: Eur Respir J 2003; 22: Suppl. 45, 378s Year: 2003
IL-10 and IL-1ra mediates OVA-induced Th2 airway allergic response at short and long-term Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury Year: 2013
Imiquimod attenuate airway inflammation and decrease the expression of TARC in allergic asthmatic mice Source: Eur Respir J 2006; 28: Suppl. 50, 224s Year: 2006
Montelukast as add-on therapy to β-agonists and late airway response Source: Eur Respir J 2007; 30: 56-61 Year: 2007
Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Deficiency of MMP-19 promotes allergen-induced eosinophil burden and airway responsiveness in mice Source: Annual Congress 2007 - Regulation of allergic airway inflammation in animal models of asthma Year: 2007
Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice Source: Eur Respir J 2009; 34: 200-208 Year: 2009
Regular salbutamol use increases CXCL8 responses in asthma: relationship to the eosinophil response Source: Eur Respir J 2003; 22: 118-126 Year: 2003
PBF-680, an oral A1 adenosine receptor antagonist, inhibits the late allergic response (LAR) in mild-to-moderate atopic asthmatics: a Phase-IIa trial Source: Virtual Congress 2020 – Cutting edge science: novel molecules and mechanisms of airway diseases Year: 2020
The CysLT1 receptor antagonist montelukast blocks bronchoconstriction induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015
The inhaled PDE4 inhibitor GSK256066 significantly inhibits airway responses following allergen challenge in asthmatics Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
Role of macrophage migration inhibitory factor in ovalbumin-induced airway inflammation in rats Source: Eur Respir J 2006; 27: 726-734 Year: 2006
The effects of a cysteinyl leukotriene receptor antagonist, pranlukast, on dendritic cell chemoattractants in the airways of subjects with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004
The Cys-LT1 receptor antagonist, pranlukast, attenuates allergen-induced increase in airway eosinophils and bone marrow derived eosinophil/basophil progenitors in subjects with atopic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 349s Year: 2003